Protacs-based enhancement for CAR-T therapies targeting TET2
This innovative approach utilizes PROTAC molecules to target the epigenetic enzyme TET2, enhancing the efficacy of CAR-T therapies by increasing the expansion and effectiveness of CD8+ T cells during ex-vivo expansion.
Overview
This novel approach leverages PROTACs (proteolysis targeting chimeras) to enhance the efficacy of CAR-T cell therapies by targeting the epigenetic enzyme TET2 during ex-vivo expansion. By modifying the phenotype of CAR-T cells, specifically increasing the CD8+ central memory cell population, this method aims to improve the persistence and anti-tumor efficacy of CAR-T treatments. The approach is positioned at the forefront of innovation, complementing recent gene-editing advancements in the field.
Technical specifications
Key features:
- Utilizes small-molecule PROTACs to degrade TET2, an epigenetic enzyme, in CAR-T cells.
- Focuses on enhancing CD8+ central memory and naïve CD8+ populations.
- Involves the synthesis of VHL and cereblon-based PROTACs.
- Biophysical characterization through techniques like Surface Plasmon Resonance (SPR) and solubility studies.
- Kinetics and specificity of degradation evaluated through proteomics and in vitro functionality assays.
Technology readiness level
This technology is currently at Technology Readiness Level 3, involving active research and development, with specific objectives for chemical synthesis, biophysical characterization, and functionality assays in progress.
About Universitat de Barcelona
The Universitat de Barcelona is a large, comprehensive public research university with an urban footprint across the city and a strong international profile. Industry connects through a university‑affiliated science and technology park that co‑locates companies with academic groups, providing shared labs, prototyping and pilot‑scale facilities, and on‑site incubation. Clinical translation is enabled by integration with leading teaching hospitals, and proximity to Barcelona’s innovation districts and global transport links supports collaboration with multinational R&D teams. Research is backed by competitive European Union programs and Spanish and Catalan public funding, and a dedicated technology transfer office manages IP, licensing, startup formation, and collaboration agreements.
delivered to your inbox.